DSSG Group: Lung

For patients with early-stage non-small cell lung cancer (NSCLC) that has been removed by surgery and who have not been treated with chemotherapy after surgery

The purpose of the ARCH study is to find out whether immunotherapy with cemiplimab helps reduce the chance of lung cancer recurring after surgery, if chemotherapy cannot be given.

PD-L1 Metastatic NSCLC

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Previously Treated, locally advanced or metastatic RAS-mutant NSCLC

RASolve 301 is a global, randomized, open-label, Phase 3 study designed to evaluate the efficacy and safety of daraxonrasib compared to docetaxel in patients with previously treated, locally advanced or metastatic, RAS-mutant NSCLC

Resectable Stage II to IIIB (N2) NSCLC

The goal of this study is to learn if people who receive V940 and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving V940 and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumours did not respond completely to treatment before surgery (neoadjuvant treatment).

Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of the study is to compare the efficacy of Nivolumab and Relatlimab Plus Chemotherapy Vs Pembrolizumab Plus Chemo for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Stage IIB-IIIB (N2) resectable NSCLC

The purpose of this study is to evaluate the efficacy and safety of adding adjuvant durvalumab after neoadjuvant chemo plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Non-squamous Non-small Cell Lung Cancer

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

This study is to see if survival and progression-free survival are better for patients on Pemrolizumab on its own or in combination with Sacituzumab Tirumotecan. Patients will be on the study maintenance treatment for just under 2 years, as long as their cancer is not getting worse or they do not have serious side effects. About 851 people will be in the study in total.

With  Advanced/Metastatic Non Small Cell Lung Cancer

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).

Metastatic non-small cell lung cancer

The purpose of this phase 3 clinical trial is to measure overall survival (OS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy.